Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What a break. Thought I was going to be here for years!!!!
Got out at $6.15
Good bye
small insider buying this past week
short interest down 700k to 1m
small caps are being slaughtered with tax selling beginning
where is the bottom???
I wish I knew
When will we be ready for the next run-up?
Get ready you all!!
Wouldn't be surprised.......
Another raise will soon be announced to take advantage of this pump
Stock will retrace to close to $3
Any thoughts?
We've had the pump no here comes the dump!!!!!
MORE DILUTION
WOW!!!!!!
EYES has become a totally manipulated trading stock
It appears to me that the merger is in jeopardy
Legal issues could also be forthcoming
While I believe mgmt made the right decision to raise capital at
this inflated PPS, I am not insure what the future will be.
This raise is just a band aid as much more capital and/or a partner is needed
Any serious comments
Sold my position at $15 simply because it was ridiculously priced at this
time IMHO
There was about 100k short position as of two weeks ago. While I would think it is much higher now, why was EYES a target? Low mkt cap, low amount of shares outstanding, potential technology? Who knows
Most, if not all of the fast money traders appear to be gone.
Where is the bottom? Here?
We s/b hearing from Mgmt. about the merger and private placement funding
as soon as this month.
Are there any investors in EYES?
Look forward to serious thoughts
Second Sight Medical Products (EYES) said Friday the Food and Drug Administration has approved the Argus 2s retinal prosthesis system in patients with retinitis pigmentosa, a genetic eye disorder that can cause vision loss.
The Argus 2s is a redesigned set of external hardware for use in combination with previously implanted artificial retina, the Argus II system.
The company said it expects the Argus 2s to be adapted as the external system for the Orion visual cortical prosthesis system, which is currently under development.
Just put my order in to buy 10M shares
at.0011
I hope to get it by the end of the week
GLTAL
Seems like an interesting company
Thinking of taking a position
Sold my position after all these long years
We all wish we had bought more more when we were at no bid but
at least I bought some
NBRI needs cash. How do they get it? I suspect another r/s and dilution
See Ya
GLTAL
thanks for the information
any feeling as to how high the mkt. cap could be?
North of 100M?
Been here for many years and endured a r/s. Fortunately bought
more at .0001
Hope we do not see another r/s down here
GLTAL
Does anyone have any idea what the market cap is?
Interesting development with the new merger with Pixium
EYES will continue to trade as a new combined company will form
This seems very positive to me
Any thoughts?
Big day today
look at the short interest
11/13/2020 117,728 (31.60)
What kind of deal is apparently coming
dilution or M & A?
Any thoughts as to whether the trials may be suspended again due to Covid.
New short interest reported as of 10/30/2020
10/30/2020 172,119 (25.76)
10/15/2020 231,844 (52.81)
09/30/2020 491,348 15.87
Is something going on behind the scenes?
Very interesting shorts report
Why are shorts covering???
Second Sight Medical Products, Inc. - Common Stock
Settlement Date Short Interest Percent Change Average Daily Share Volume
Days to Cover
10/15/2020 231,844 (52.81) 151,233 1.53
09/30/2020 491,348 15.87 200,993 2.44
09/15/2020 424,037 (30.70) 444,430 1.00
08/31/2020 611,920 18.58 673,399 1.00
08/14/2020 516,019 (2.81) 184,172 2.80
07/31/2020 530,922 (13.08) 446,119 1.19
07/15/2020 610,788 3.54 369,922 1.65
06/30/2020 589,925 (6.17) 606,933 1.00
06/15/2020 628,735 (11.22) 2,538,472 1.00
05/29/2020 708,177 (3.42) 709,566 1.00
05/15/2020 733,232 (5.33) 720,305 1.02
04/30/2020 774,552 8.99 272,130 2.85
Notice of Delisting or Failure to Satisfy a Continued Listing
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
Letter from Nasdaq dated October 1, 2020
On October 1, 2020, Second Sight Medical Products, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) advising the Company that for 30 consecutive business days preceding the date of the Notice, the bid price of the Company’s common stock had closed below the $1.00 per share minimum required for continued listing on the Nasdaq Capital Market (the “Minimum Bid Price Requirement”) as required by Nasdaq Listing Rules.
The Notice has no effect on the listing of the Company’s common stock at this time, and the Company’s common stock continues to trade on The Nasdaq Capital Market under the symbol “EYES.”
Under Nasdaq Listing Rule 5810(c)(3)(A), if during the 180 calendar day period following the date of the Notice (the “Compliance Period”), the closing bid price of the Company’s common stock is at or above $1.00 for a minimum of 10 consecutive business days, the Company will regain compliance with the Minimum Bid Price Requirement and its common stock will continue to be eligible for listing on the Nasdaq Capital Market absent noncompliance with any other requirement for continued listing.
If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period, under Nasdaq Listing Rule 5810(c)(3)(A)(ii), if on the last day of the Compliance Period the Company is in compliance with the market value of publicly held shares requirement for continued listing, as well as all other standards for initial listing of its common stock on the Nasdaq Capital Market (other than the bid price requirement), the Company may be eligible for additional time if the Company also provides written notice to Nasdaq of its intention to cure the deficiency during a second compliance period at which point Nasdaq may grant the Company an additional 180 days to regain compliance with the Minimum Bid Price Requirement.
If the Company does not regain compliance with the Minimum Bid Price Requirement by the end of the Compliance Period (or the Compliance Period as may be extended) the Company’s common stock will be subject to delisting.
The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules.
A list of all non-compliant Nasdaq companies and the reason(s) for such non-compliance is posted on Nasdaq’s website at listingcenter.nasdaq.com. The Company will be included in this list commencing five business days from the notification date.
Date: October 2, 2020
SECOND SIGHT MEDICAL PRODUCTS, INC.
Matthew Pfeffer
LOS ANGELES--(BUSINESS WIRE)--Sep. 22, 2020-- Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the resumption of its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System (“Orion”) at UCLA Medical Center (“UCLA”). The study, which includes four participants at UCLA and two participants at Baylor College of Medicine (“Baylor”), was paused for in-person visits following the guidelines for clinical trials at each institution in March 2020 due to COVID-19. Study visits have now been resumed; several UCLA participants are being examined this week, and Baylor is anticipated to resume its study soon.
The first human subject was implanted with Orion in January 2018. A total of six subjects have been implanted in the Orion Early Feasibility Study.
“We are delighted that the Early Feasibility Study has restarted. The study, like many such investigations, was suspended as medical centers focused attention and resources on their COVID-19 response and to protect the health of study participants. Our highest priority remains the health and safety of all of our study participants, and we look forward to continuing this important research. We remain committed to this innovative technology and believe that Orion has the potential to safely benefit blind individuals and help them to perform everyday tasks,” stated Matt Pfeffer, Acting Chief Executive Officer.
Orion is a breakthrough technology intended to provide useful artificial vision to individuals who are blind due to a wide range of causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. Orion converts images captured by a miniature video camera mounted on glasses into a series of small electrical pulses transmitted wirelessly to electrodes implanted directly on the visual cortex of the individual subject’s brain.
In June 2019, the study’s principal investigators, Nader Pouratian, MD, Ph.D. of UCLA and Daniel Yoshor, MD of Baylor, presented 12-month results from the Early Feasibility Study at the World Society for Stereotactic and Functional Neurosurgery Annual Meeting in New York City. On both the primary and secondary outcome measures, latest results at 12 months have been positive.
This is the 2nd CFO to resign this year
When do we ever see good news again?
This can not be good news. I suppose FDA approval and/or funding
not imminent
On, August 31, 2020, John T. Blake, Chief Financial Officer of Second Sight Medical Products, Inc. (the “Company”), submitted his resignation from all positions effective September 4, 2020 to pursue other opportunities. Edward Sedo, Controller, has been appointed Principal Accounting and Financial Officer and will assume the majority of Mr. Blake’s duties.
They will not have to raise $$$ until the trials at UCLA resume. When will
that be? At some point maybe Greg Williams will resume funding the company
His insider ownership is about 43% down from 63%, excluding his warrants
What is the value of Orion if things progress. Any idea?
I am waiting to see the 2nd qtr. institution stats and to see if any insider purchases
Is Delisting a reality?
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
Letter from Nasdaq dated June 1, 2020
On June 1, 2020, The Nasdaq Stock Market (“Nasdaq”) notified Second Sight Medical Products, Inc. (the “Company”) that following the resignation of William J. Link, effective May 31, 2020, the Company is non-compliant with Nasdaq’s independent director and audit committee requirements as set forth in Listing Rule 5605 (the “Listing Rules”) due to more than one vacancy on its board and audit committee. Nasdaq had previously notified the Company on April 15, 2020 that due to the appointment of Matt Pfeffer as Acting Chief Executive Officer of the Company, the Company no longer complied with the Listing Rules and that consistent with Listing Rules 5605(b)(1)(A) and 5605(c)(4) the Company was provided with a cure period in which to regain compliance. As a result, Nasdaq indicated that the Company is no longer eligible for the cure period and must submit a plan of compliance no later than July 16, 2020, which is 45 days after the notification date. If the plan is accepted, the Company can be granted an extension of up to 180 calendar days from the notification date to evidence compliance. If the plan is not accepted, the Company may appeal before a Nasdaq Hearing Panel.
And you wonder where the money from the raise is going.....
in recognition of his services on behalf of the Company
Thanks Mr. Blake for this doing this raise and the dilution
Wish shareholders could recover for losses by this totally mismanaged company.
On May 13, 2020 Second Sight Medical Products, Inc. (the “Company”) and John T. Blake, Chief Financial Officer of the Company, entered into Amendment No.1 (the “Amendment”) to Executive Employment Agreement dated March 21, 2018 (the “Employment Agreement”) pursuant to which the Company agreed to pay Mr. Blake a one-time cash bonus of $100,000 (the “Bonus”) in recognition of his services on behalf of the Company. Under the Amendment, Mr. Blake will be entitled to receive all separation amounts due to him pursuant to the Employment Agreement less the amount of Bonus in the event that his employment is terminated without cause (as defined in the Employment Agreement)
What is the value of ORION?
With short interest still rising and even a jump for EYESW,
I am still looking for a reason to buy back
Operations have ceased, most of the personnel have been terminated and the
trials have been halted
What was the reason for the highly dilutive raise?
ORION is there only asset
Are there any buyers and at what price?
Here's where some of the money is going from the last raise.
See below
The stock PPS is actually holding up well. This is partially due to the lockup of the shares for 6 months and the lack of shares
held by the public
What is Williams thinking? He has invested close to $80M and just
did an offering at a huge discount and dilution. Operations are
shut down and there are substantial layoffs,
What is the value of the technology and will the company be sold
or just close?
On May 8, 2020, the board of directors of Second Sight Medical Products, Inc. (the “Company”) approved payment to Patrick Ryan, former Chief Operating Officer of the Company, of approximately $471,000 and to reimburse up to 12 months of COBRA, if elected, pursuant to the terms of Mr. Ryan’s employment agreement with the Company. Mr. Ryan was separated effective April 17, 2020 as part of a second reduction of work force implemented under a previously announced winding down of operations.
The Company is unable to meet the filing deadline for its Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 (the “Quarterly Report”) due to significant disruption in its operations by the COVID 19 pandemic, including the closure of its offices, material reductions in personnel and remote working arrangements that have resulted in delays in the Company’s accounting procedures and quarterly review by its independent auditors. The Company estimates that the Quarterly Report will be filed no later than June 29, 2020 (45 days after its due date) and will (i) disclose that the Company is relying on the Order, (ii) state the reasons why it could not file the Quarterly Report on a timely basis and (iii) will contain an appropriate Risk Factor disclosure on the potential and actual impact of COVID-19 on the Company.
The extent of COVID-19’s effect on the Company’s operational and financial performance will depend on future developments, including the (i) duration, spread and intensity of the outbreak, (ii) the Company’s ability to directly resume operations within its offices, (iii) impact to employees who may contract the disease or be subject to quarantine, (iv) the ability to reach agreements to joint venture or partner with others on continued development of the Orion system, and (v) securing additional financing, all of which are uncertain and difficult to predict considering the rapidly evolving landscape. As a result, the Company is unable to ascertain the overall impact of COVID-19 on its business. However, if the pandemic continues to evolve into a severe worldwide health crisis, the disease could have a material adverse effect on its business, results of operations, financial condition and cash flows and adversely impact the trading price of its common stock.
I sold my position months ago and don't see any reason to buy at this level
I think we might see much lower levels soon
Volume in the warrants is interesting though
All IMHO
offering for $1 closes today
where will the bottom be?
I don't think we have seen it yet.....
Oncocyte Announces Peer-Reviewed Publication of Data Demonstrating the Potential of its TNBCType Assay to Inform Triple Negative Breast Cancer Drug Development
Peer reviewed research demonstrates the utility of the Oncocyte’s TNBCType-IM assay to identify the most suitable cell lines to help biopharma and academic researchers in their quest for treatments for TNBC, the deadliest form of breast cancer
Published research demonstrates the test’s ability to work consistently both in vitro and in vivo in six cell lines used in drug development, suggesting promise in research applications
IRVINE, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the peer-reviewed publication of data underscoring the potential of its TNBCType assay for use in triple negative breast cancer (TNBC) pharmaceutical research. The paper, entitled “Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: implications for translational research”, was written by collaborators at The University of Texas MD Anderson Cancer Center and demonstrates the ability of the assay to work consistently across six cell lines typically used in drug development, both in vivo and in vitro. The findings were published in the peer-reviewed journal PLOS One.
Breast cancer is the most common cancer with more than 1.6 million new cases diagnosed annually in the world. In the United States, the overall 5-Year survival rates in breast cancer are over 90%, but survival rates for triple negative breast cancer (TNBC) are lower at 77%. TNBC is generally more aggressive than other types of breast cancer and is the focus of intense research by biopharmaceutical companies with over 100 clinical trials and several discovery-phase programs in process. TNBCType-IM is a 101 gene assay that measures the amount of RNA from a biopsy or surgical specimen and then uses a proprietary algorithm to classify patients into five subtypes associated with response to four different types of therapeutics including immune-therapy (PD-1/PD-L1), targeted therapies (PARP inhibitors and AR receptor) and cytotoxic chemotherapy. The Company believes that the assay may be an attractive companion diagnostic candidate for proprietary therapeutics in development at biopharmaceutical companies.
In the study, researchers established tumor xenografts from 17 TNBC cell lines that were then subjected to gene expression profiling with a 2188-gene algorithm, TNBCType, and Oncocyte’s revised 101-gene algorithm TNBCtype-IM. A total of six cell lines were identified as maintaining consistent subtype classification between in vitro and in vivo tumor xenograft analyses by Oncocyte’s TNBCtype-IM algorithm, suggesting they may be the optimal cell lines for use in subtype specific TNBC drug development and translational research.
Naoto Ueno, M.D., Ph.D., Professor of Breast Medical Oncology at MD Anderson Cancer Center and the lead author of the study, said, "In developing new therapies for TNBC, it is important to have cell lines that are stable both in vitro and in vivo to show the drug’s effectiveness. This research will help pharma and academic researchers know which cell lines to use to identify the most promising therapeutic candidates to personalize the cancer treatment in TNBC."
“The data published in this manuscript reinforce the potential clinical importance of TNBC classification,” added Doug Ross, M.D., Ph.D., Chief Medical Officer of Oncocyte. “This information will help bridge the gap between drug development and the potential use of TNBCtype for making clinical decisions.”
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx™, the company’s liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients’ lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.
DetermaDx, DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.
Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx™
May lead to Medicare coverage for up to 70% of eligible early-stage lung cancer patients
Email Print Friendly Share
April 30, 2020 14:21 ET | Source: OncoCyte Corporation
IRVINE, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that Palmetto, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a final local coverage decision for DetermaRx™. The test, which launched earlier this year via an early access program, is the first and only predictive test for the identification of patients with Stage I-IIA non-squamous NSCLC who are at high-risk for recurrence following surgery and are likely responsive to adjuvant chemotherapy.
“Today’s CMS decision is a significant milestone for Oncocyte. Not only can we now increase outreach to more patients and physicians around the country, but we believe several national and regional payers will follow this decision, giving additional patients insurance coverage for this important test,” said Ron Andrews, CEO of Oncocyte. “The DetermaRx test addresses a critical unmet need for the 30-50% of patients with early-stage lung cancer who have a recurrence despite having “curative” surgery. In a published clinical study, patients identified as high-risk by the DetermaRx test post-surgery and treated by chemotherapy had survival rate of 92% compared to high-risk untreated patients who had a survival rate of 49%.”
“Despite the impact of COVID-19, we have seen significant interest in this test just in the first quarter of launch, with twenty onboarded sites and more than 1500 attendees to physician education programs. Today’s CMS decision further supports the promise of DetermaRx, and we are looking forward to expanding our reach throughout the U.S. over the coming months.”
Following this decision, Oncocyte intends to intensify its efforts with private payers who have a history of following Medicare coverage decisions, with the goal of securing coverage for patients with private insurance.
Please visit CMS.gov to view the final local coverage decision memo.
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx™, the company’s liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients’ lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies. DetermaDx, DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.
Public offering of 7,500,000 shares of common stock at an offering price of $1.00 per share
LOS ANGELES--(BUSINESS WIRE)--Apr. 30, 2020-- Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of an underwritten public offering of 7,500,000 shares of common stock, no par value (the “Common Stock”) at an offering price of $1.00 per share of Common Stock for aggregate gross proceeds of $7,500,000, prior to deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on May 5, 2020, subject to the satisfaction of customary closing conditions.
Second Sight Medical Products intends to use the net proceeds from the offering for accrued expenses, working capital and general corporate purposes, which may include, without limitation, engaging in partnerships, business combinations, or acquisitions or investing in businesses that may or may not be related to its current operations.
ThinkEquity, a division of Fordham Financial Management, Inc., is acting as representative of the underwriters in the offering.
A shelf registration statement on Form S-3 (File No. 333-221228) relating to the shares of common stock to be issued in the proposed offering was filed with the Securities and Exchange Commission (SEC) and is effective. A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering was filed by the Company with the SEC. The securities may be offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from ThinkEquity, a division of Fordham Financial Management, Inc., 17 State Street, 22nd Floor, New York, New York 10004, by telephone at (877) 436-3673, by email at prospectus@think-equity.com. Electronic copies of the preliminary prospectus supplement and accompanying prospectus will also be available on the SEC’s website at http://www.sec.gov.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Oncocyte Announces Distribution Agreement with CORE Diagnostics, Expanding Commercial Availability of DetermaRx™ to India, the Middle East and Africa
In the United States, DetermaRx™ has rapidly gained traction, expanding to 18 sites in the first three months since commercial launch
IRVINE, Calif., April 23, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has entered a distribution agreement with CORE Diagnostics, expanding the commercial availability of DetermaRx™ to India, the Middle East and Africa. DetermaRx™ is Oncocyte’s treatment stratification test that identifies patients at high risk for lung cancer recurrence, who may benefit from adjuvant chemotherapy post-surgery.
CORE Diagnostics is one of the fastest-growing clinical laboratories in India, focused on bringing the most advanced testing techniques and expertise to the country. Under the terms of the agreement, tissue samples needed for the test will be run in the United States by Oncocyte, while CORE Diagnostics will generate test orders and provide customer service to patients.
“As we think about expanding beyond the U.S., one of our strategies is to partner with labs focused on delivering high value, proprietary diagnostics into an existing oncology channel to generate demand and brand awareness. CORE Diagnostics does exactly that,” said Ron Andrews, Chief Executive Officer of Oncocyte. “We believe CORE’s oncology salesforce of 100 people and customer base of 5000 ordering physicians in 12 different countries will be critical as we work to increase awareness and availability of our tests among physicians and patients globally. We are thrilled to embark on this collaboration with such a respected and growing brand in this important market and are looking forward to tens of thousands more patients having access to our tests, potentially saving lives in the process. As we continue to grow, we intend to extend this distribution model to other geographies including South America and other parts of Asia as well.”
Zoya Brar, Chief Executive Officer and Founder of CORE Diagnostics added, “The market for molecular testing in India and the Middle East is quite large. We focus on partnering with labs that offer proprietary diagnostics fulfilling an unmet need at a patient friendly price for our population, and we believe DetermaRx perfectly fits these characteristics. We look forward to making this test and potentially other diagnostic tests from Oncocyte available across these countries in the future.”
DetermaRx was launched in the United States through an Early Access Program (EAP) in late January 2020 with two sites. Since then it has continued to gain traction, rapidly expanding to eighteen sites in just the first three months of launch. These targeted sites are located across the country including multiple community cancer centers where early stage cancer is managed including physicians from large community-based systems, such as Dignity Health and Northshore Oncology. The Company has onboarded eight sites in the past month despite COVID-19 challenges throughout the country. Oncocyte will begin serving physicians in these sites once surgeries for early stage lung cancer ramp back up over the coming months.
“We’re thrilled with the progress made thus far to expand the availability of DetermaRx, both in the U.S. and beyond,” said Padma Sundar, Senior Vice President, Marketing and Market Access at Oncocyte. “I’m incredibly proud of our team’s rapid pivot to virtual operations as the COVID-19 situation began to progress and am confident that the quick expansion in DetermaRx test adoption sites was driven by this foresight. Our online peer-to-peer physician engagement initiatives have reached over 1500 participants. Additionally, we’ve seen success with virtual onboarding of sites using sophisticated physician office-friendly software for easy test ordering, processing and delivery of test reports, as well as prompt customer service. We intend to take these same steps to ensure similar expansion outside of the U.S. and are looking forward to continued progress.”
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx™, the company’s liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients’ lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies.
DetermaDx, DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.
Still not sure why Gregg Williams would step away after all the money he has invested and why another candidate would not be interested in acquiring the company and/or technology, without a fire sale.
Regardless of what happens, this was poorly managed and certainly open to litigation by shareholders IMO
This might be the reason for the volatility in EYES
EYES would certainly be a candidate for funding to resume the trials
NEWS PROVIDED BY
Foundation Fighting Blindness
May 09, 2019, 17:44 ET
Foundation Fighting Blindness Endorses 'Eye Bonds' Legislation
Bipartisan Bill Will Stimulate Up to $1 Billion in New Funding for Blindness Research
COLUMBIA, Md., May 9, 2019 /PRNewswire/ -- The Foundation Fighting Blindness today announced its support for bipartisan legislation to fund treatments and cures for blindness and other forms of severe vision impairment. H.R. 2620, the Faster Treatments and Cures for Eye Diseases Act, introduced today by Reps. Sanford Bishop (D-GA) and Cathy McMorris Rodgers (R-WA), would create a five-year pilot program for the creation of Eye Bonds – financial instruments to raise money for research specifically related to a broad range of eye diseases and conditions.
"On behalf of the entire blind and vision impaired community, we are grateful for the actions by these members of Congress and urge others to join as co-sponsors of this important legislation. There is no doubt that vision-saving and vision-restoring research sitting on shelves needs to be unleashed so patients can benefit. We are confident that Eye Bonds will work," says?Benjamin Yerxa, PhD, chief executive officer at the Foundation. "We especially want to thank?Karen and Basil Petrou, longtime Foundation leaders, for developing the Eye Bonds concept and the financial details that make the legislation so beneficial and safe for taxpayers."
Eye Bonds would spur private-sector investment in translational research and advance treatments and cures for blindness and other causes of severe vision impairment. If approved by Congress, the new bonds would finance packages of loans that would total?$1 billion?for new projects over five years of the pilot program. Underwriters would determine how many projects they would fund and at what amount, not to exceed?$250 million?in any year. The National Eye Institute (NEI), part of the National Institutes of Health, would evaluate programs eligible for funding, although NEI would have no risk related to funding these projects.
Eye Bonds would NOT replace existing federal funding to the NEI.
Eye Bonds may be purchased by pension funds, insurance companies, and other institutional investors. The money generated will then be lent to scientific projects recommended by the NEI. When the bond matures, or comes due, the scientific project will have reached a stage of development that it will have commercial value or be eligible for other funding, enabling the loan recipient to repay the Eye Bond. Eye Bonds will be backed by a limited federal guarantee to provide the security needed for pension funds and other private investors to purchase them.
This legislation holds enormous promise for saving and restoring the vision of the 4 million adults and almost half-a-million children in the U.S. who are blind or have severely impaired vision from a variety of eye diseases and conditions, including age-related macular degeneration, diabetic retinopathy, and sickle-cell retinopathy. Furthermore, Eye Bonds would advance treatments and cures for diseases and conditions that affect the entire eye, including the severe vision trauma suffered by veterans of wars in?Iraq?and?Afghanistan.
Eye Bonds fill a critical need, because many promising therapies never make it through the translational research process — out of labs and into clinical trials — because of a lack of funding; translational research is often referred to as "crossing the Valley of Death" for this reason. Pharmaceutical companies and biotechs are less likely to fund translational research. They prefer to fund projects once they have had some initial success in a clinical trial. This is even more the case with rare diseases or conditions without a proven regulatory pathway or demonstrated commercial success. Eye bonds would fund this vital research at minimal risk to the taxpayer, who would be the first to be repaid when private investors recoup their investments.
The Foundation believes these innovative research bonds will prove successful and the concept could be used to overcome obstacles that also exist in translating cancer, Alzheimer's, Parkinson's and other disease research into practical use.
The Foundation Fighting Blindness has been an unparalleled leader in supporting research on inherited retinal diseases for more than 48 years. It is currently funding 75 research studies at prominent laboratories worldwide and on the spectrum of emerging retinal disease therapies including gene, cell and drug-based treatments.
ABOUT FOUNDATION FIGHTING BLINDNESS
The Foundation Fighting?Blindness was established in 1971. It has since raised more than?$750 million?for research aimed at preventing, treating and curing blindness caused by retinal degenerative diseases. In excess of 10 million Americans, and millions more worldwide, have experienced or are at risk of experiencing vision loss due to retinal degeneration. Through its support of focused and innovative science, the Foundation drives the research that has and will continue to improve the lives of people affected by retinitis pigmentosa, macular degeneration, Usher syndrome and other inherited retinal diseases. The Foundation has launched a global patient registry,?www.MyRetinaTracker.org, to build knowledge of retinal diseases and advance clinical research. Visit?www.FightBlindness.org?for the latest information on retinal disease research. Follow the Foundation on?Facebook?and?Twitter.
Contact:
Ben Shaberman
bshaberman@fightblindness.org?
410-499-9158
SOURCE Foundation Fighting Blindness
Oncocyte to Participate at 19th Annual Needham Virtual Healthcare Conference
IRVINE, Calif., April 07, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that company management will participate in the 1-on-1 meetings at the upcoming 19th Annual Needham Virtual Healthcare Conference from Tuesday, April 14, 2020 through Wednesday, April 15, 2020.
Interesting company
Anyone want to start a dialogue?